Repeat Pharmaceutical Fraud Settlements: What Changed Between the Same Company’s Cases?

Repeat pharmaceutical fraud settlements put the same company name over different payment schemes, overlapping conduct periods and businesses acquired after the conduct occurred. Pfizer’s cases span promotion, Medicaid rebates and an acquired company’s speaker payments. Novartis’s reach from prescribing incentives into pharmacy refills. AstraZeneca’s move from promotion to formulary contracts and price reporting. Which payments changed, which incentives survived, and what did the people reviewing them actually see?

The Settlement Date Is Only Part of the Story

A settlement date tells you when a company resolved a case. The conduct dates tell you when the disputed business operated. The acquisition date can explain why a different company is paying for it.

Public Citizen’s 2018 study, Twenty-Seven Years of Pharmaceutical Industry Criminal and Civil Penalties: 1991 Through 2017, assigns an acquired company’s settlement to its new owner, even when the conduct preceded the purchase. For an insider, ownership during the conduct matters: who chose the program, who approved the payments, and what the buyer did when it took control.

Pfizer’s Later Settlements Reached Acquired Businesses

Pfizer’s own promotion settlement came before later payments involving Wyeth and Biohaven. The Protonix conduct preceded Pfizer’s purchase of Wyeth. Biohaven’s speaker programs ended when Pfizer acquired the company.

Promotion and Prescribing Incentives in 2009

Pfizer agreed to a $1 billion civil settlement in September 2009. The government alleged that promotion of Bextra, Geodon, Zyvox and Lyrica caused government health care programs to pay for uses they did not cover. It also alleged kickbacks to induce prescriptions of those and other drugs.

Whistleblower cases triggered the investigation.

Pfizer also agreed to a corporate integrity agreement with the Department of Health and Human Services’ inspector general. The agreement required procedures and reviews aimed at detecting similar conduct, annual compliance certifications from senior executives and board members, and public disclosures. The response reached beyond the sales representative to the people supervising the business.

Wyeth’s Rapamune Promotion

Wyeth’s July 2013 Rapamune resolution included a civil settlement over alleged promotion for unapproved uses. The announcement identified Wyeth as a company Pfizer had acquired. The government’s account described financial incentives encouraging the sales force to target transplant patient populations to increase Rapamune sales.

That alleged incentive sits behind the promotional message. The employee’s target and compensation help explain why particular prescriptions were pursued.

Wyeth’s Hospital Discounts and Medicaid Rebates

Wyeth and Pfizer’s April 2016 settlement was $784.6 million over allegedly concealed Protonix discounts. The government said Wyeth underpaid Medicaid rebates from 2001 to 2006. Pfizer acquired Wyeth in 2009, after that conduct. The later payment concerned an acquired company’s rebate obligations, rather than Pfizer’s own promotional activity.

The commercial logic began in the hospital. According to the government’s complaint, Wyeth bundled discounts on Protonix Oral and Protonix IV to get hospitals to use the oral drug. Patients discharged on Protonix Oral were likely to keep taking it, while Medicaid and other payers would pay nearly full price afterward. A hospital discount could help secure the prescription long after discharge.

Medicaid’s rebate system made those discounts consequential. Manufacturers report qualifying best prices that help determine the rebates owed to state Medicaid programs. The government alleged that Wyeth hid the bundled discounts from that reporting, leaving Medicaid without the reduction it was owed.

Here the disputed transaction was a hospital discount, rather than a sales pitch. The central comparison was between the discount offered to the hospital and the price reported to the government.

Biohaven’s Speaker Programs Ended at Acquisition

Pfizer’s smaller January 2025 settlement concerned a different acquired business: it agreed to pay $59,746,277 on behalf of Biohaven to resolve allegations concerning the migraine drug Nurtec ODT. The settlement covered alleged improper payments from March 2020 through September 2022.

The government alleged that Biohaven selected prescribers for paid speaking opportunities to induce prescriptions. It also alleged that some attendees returned to programs on the same topic without receiving an educational benefit, while others included speakers’ spouses, family members, friends or colleagues with no educational need to attend. Honoraria and meals at expensive restaurants were the alleged inducements.

The government said the conduct persisted until October 2022, when Pfizer acquired Biohaven and terminated the Nurtec speaker programs. That is a concrete change at acquisition. Pfizer made the settlement agreement. Biohaven had run the alleged program before the purchase.

Novartis’s Cases Followed Different Routes to the Prescription

Novartis’s settlements reached promotion, specialty-pharmacy referrals and physician speaker payments.

Promotion and Kickback Allegations in 2010

Novartis’s September 2010 resolution included a civil settlement over alleged promotion of Trileptal for noncovered psychiatric and pain uses and kickbacks involving a group of its drugs. Former employees brought the whistleblower cases.

The compliance measures described for Novartis at that time included review of promotional activities, executive certifications, disclosure of physician payments and board review with outside expertise. These controls addressed what the company said to prescribers, what it paid them and who reviewed that activity.

The Pharmacy Refill Became a Sales Target

The November 2015 specialty-pharmacy settlement included $370 million to resolve federal and state false claims allegations. The government alleged that Novartis used referrals and rebates to induce pharmacies to recommend Exjade refills and switches to Myfortic.

Exjade’s distribution made the referral valuable. The government described a closed network in which Novartis controlled assignments of patients among specialty pharmacies. It said the company gave more referrals and higher rebates to pharmacies that obtained higher refill rates. The alleged incentive scheme operated from 2008 to 2012, spanning the earlier resolution.

The sales target reached the patient through someone presented as a source of clinical advice. The government’s amended complaint alleged:

The government also alleged that pharmacy calls emphasized Exjade’s benefits while understating serious risks. For Myfortic, the alleged bargain was different: rebates in return for pharmacies recommending that doctors switch patients from competing drugs. Both arrangements put a commercial incentive behind advice delivered through a healthcare provider.

Novartis made factual admissions about its specialty-pharmacy relationships and accepted responsibility for those admissions. The settlement also amended its existing integrity agreement to put those relationships under independent review and extend the agreement by five years. The controls now expressly reached the pharmacy channel.

The Speaker Settlement Looked Back to Earlier Dinners

Novartis’s July 2020 speaker-program resolution included $591,442,009 in federal False Claims Act damages. Even the federal damages exceeded the earlier pharmacy settlement. The alleged conduct period was 2002 through 2011, overlapping the earlier promotion settlement.

Novartis admitted that some sales representatives intended speaker honoraria to induce prescribing. Doctors repeatedly dined with familiar groups and sometimes rotated the paid speaking role. The company also admitted paying honoraria for purported events that never occurred. A sales representative used fake restaurant receipts to obtain gift cards for high-prescribing doctors.

The problem reached the company’s own compliance messaging. The admissions described training that discouraged written communications about improper conduct and suggested using the phone. Compliance training was telling employees to leave less of a written record.

The 2020 restrictions allowed speaker programs only in limited circumstances and required a virtual format. Compared with the earlier disclosure and review requirements, this changed the permitted setting of the program itself. An expensive dinner could no longer be the venue for a permitted speaker event.

AstraZeneca’s Cases Moved From Promotion to Contract Terms

AstraZeneca’s later civil settlements concerned different decisions from the promotional conduct behind its Seroquel resolution. One concerned the terms used to secure a drug’s formulary position. Another concerned the fees deducted when calculating Medicaid rebates.

AstraZeneca’s April 2010 Seroquel civil settlement concerned alleged promotion for unapproved uses that caused noncovered claims, including payments to doctors recruited as authors of company-prepared articles.

The February 2015 Nexium settlement was $7.9 million. The government alleged that AstraZeneca gave Medco price concessions on Prilosec, Toprol XL and Plendil in return for sole and exclusive formulary status for Nexium, causing claims to the Retiree Drug Subsidy Program.

The discounted drugs and the favored drug were different. Looking only at Nexium’s own price would miss the alleged exchange.

A formulary is the covered-drug list, and its placement decisions help determine which products reach insured patients. Manufacturer rebates can purchase access and preferred placement. That industry arrangement explains why an account contract can matter as much as a sales presentation: the concession may influence the product’s position before a prescription reaches the pharmacy.

The larger July 2015 rebate settlement was $46.5 million. The government alleged that AstraZeneca improperly deducted wholesaler service fees from average manufacturer prices, reducing quarterly Medicaid rebates.

Here the disputed decision was in the calculation. A fee’s treatment changed the reported price used to determine what the manufacturer owed Medicaid. Across these matters, the same company name leads to different records: promotional articles, formulary concessions and reporting calculations.

What Changed in the Business After the Agreement?

The clearest documented changes concern particular transactions. Pfizer’s earlier agreement required executive and board certifications. Novartis’s pharmacy settlement extended independent review to specialty-pharmacy relationships. Its later speaker restrictions changed the format of permitted events. Pfizer ended Biohaven’s speaker programs when it bought the company.

Novartis’s admissions show why a payment disclosure leaves further questions. A physician-payment entry can identify a paid speaker, while attendance and expense records explain whether there was a real audience or even a real event. In the pharmacy channel, a rebate amount makes more sense beside the referral allocation and the refill target that earned it.

What Evidence Is Needed to Prove Fraud?

Proving pharmaceutical fraud means connecting the payment or pricing decision to the government claims or rebates it affected. We work through that connection with you, including when the practice operated and who controlled it.

An insider can explain why a doctor was selected, what a pharmacy had to do to receive referrals, or how a fee entered the reporting calculation. That business knowledge gives a whistleblower case its focus. A prior settlement supplies a useful comparison for discussing what you have seen with us.

How Much Money Do Pharmaceutical Whistleblowers Get for Exposing Fraud?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In the Biohaven matter, the former sales representative who brought the case was to receive approximately $8.4 million from the federal recovery. The person who knows how the program actually worked can bring something the settlement headline never shows.

You Know What Changed Inside the Company

If the payments, refill targets or pricing decisions sound familiar, speak to one of our whistleblower experts about what you have seen. We build your strongest pharmaceutical whistleblower case around your knowledge of the business and bring in pharmaceutical fraud whistleblower lawyers who understand the contracts, claims and compliance history. We work beside you from that first account through the decisions that shape your case.